Trump's 100% Drug Tariffs: What You Need to Know
Trump's 100% tariffs on imported brand-name drugs include tiered exemptions for companies committing to U.S. manufacturing and price reductions.
Michael O'Connor
Neuroscience Editor
NeuroscienceNeurological DisordersPsychiatric ResearchBrain Research
About Michael
Michael O'Connor is a neurologist and researcher at Tripler Army Medical Center in Honolulu. Board-certified in neurology and clinical neurophysiology, he covers brain research, neurological disorders, and psychiatric studies for Hawaii Medical Journal. Previously, Michael was a Editorial Fellow at STAT News. Michael holds a B.A. in Science Communication from University of Hawaii at Manoa.
Articles by Michael
Parenting Challenges in Primary Care: The GP Workforce Gap
The suspension of GP Helen Eisenhauser highlights how primary care systems fail to support physician-parents, especially women managing childcare demands.
Electronic Marking Systems to Prevent Medical Exam Errors
The AoMRC has issued guidance urging royal colleges to adopt electronic marking systems after a blunder affected nearly 300 physician exam candidates.
Pfizer Lyme Vaccine Shows 70% Efficacy But Misses Statistical Goal
Pfizer and Valneva's Lyme disease vaccine reduced infection risk by over 70%, but failed to meet its prespecified statistical threshold in clinical trials.
24 States Sue EPA Over Greenhouse Gas Endangerment Rollback
A 24-state coalition sues the EPA over its rescission of the 2009 endangerment finding, with major public health and climate regulation implications.
Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.
Updated NICE Guidance: Chronic Heart Failure in Adults
NICE updates chronic heart failure guidance, covering pharmacological optimisation across ejection fraction subtypes and IV iron supplementation recommendations.
Camrelizumab Plus CAPOX Improves Survival in Gastric Cancer
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.